|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SP3 |
Gene summary for SP3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SP3 | Gene ID | 6670 |
| Gene name | Sp3 transcription factor | |
| Gene Alias | SPR2 | |
| Cytomap | 2q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q02447 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6670 | SP3 | P80T-E | Human | Esophagus | ESCC | 7.40e-15 | 5.26e-01 | 0.155 |
| 6670 | SP3 | P82T-E | Human | Esophagus | ESCC | 1.76e-06 | 2.24e-01 | 0.1072 |
| 6670 | SP3 | P83T-E | Human | Esophagus | ESCC | 4.42e-10 | 3.81e-01 | 0.1738 |
| 6670 | SP3 | P84T-E | Human | Esophagus | ESCC | 3.21e-05 | 2.92e-01 | 0.0933 |
| 6670 | SP3 | P89T-E | Human | Esophagus | ESCC | 1.30e-07 | 4.22e-01 | 0.1752 |
| 6670 | SP3 | P91T-E | Human | Esophagus | ESCC | 2.73e-10 | 9.84e-01 | 0.1828 |
| 6670 | SP3 | P107T-E | Human | Esophagus | ESCC | 3.77e-13 | 3.68e-01 | 0.171 |
| 6670 | SP3 | P126T-E | Human | Esophagus | ESCC | 1.75e-04 | 4.47e-01 | 0.1125 |
| 6670 | SP3 | P127T-E | Human | Esophagus | ESCC | 6.78e-21 | 3.29e-01 | 0.0826 |
| 6670 | SP3 | P128T-E | Human | Esophagus | ESCC | 1.13e-19 | 6.81e-01 | 0.1241 |
| 6670 | SP3 | P130T-E | Human | Esophagus | ESCC | 1.88e-32 | 8.49e-01 | 0.1676 |
| 6670 | SP3 | S43 | Human | Liver | Cirrhotic | 3.80e-02 | -2.54e-02 | -0.0187 |
| 6670 | SP3 | HCC1_Meng | Human | Liver | HCC | 3.32e-48 | -4.92e-02 | 0.0246 |
| 6670 | SP3 | HCC2_Meng | Human | Liver | HCC | 3.89e-28 | 8.85e-02 | 0.0107 |
| 6670 | SP3 | HCC1 | Human | Liver | HCC | 2.55e-05 | 3.57e+00 | 0.5336 |
| 6670 | SP3 | HCC2 | Human | Liver | HCC | 4.96e-02 | 2.92e+00 | 0.5341 |
| 6670 | SP3 | Pt13.b | Human | Liver | HCC | 7.63e-03 | -4.67e-02 | 0.0251 |
| 6670 | SP3 | S014 | Human | Liver | HCC | 3.16e-05 | 4.19e-01 | 0.2254 |
| 6670 | SP3 | S015 | Human | Liver | HCC | 2.47e-05 | 4.74e-01 | 0.2375 |
| 6670 | SP3 | S016 | Human | Liver | HCC | 1.73e-04 | 4.03e-01 | 0.2243 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
| GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
| GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
| GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
| GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
| GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
| GO:000226210 | Cervix | CC | myeloid cell homeostasis | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
| GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
| GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
| GO:00018908 | Cervix | CC | placenta development | 40/2311 | 144/18723 | 4.59e-07 | 1.77e-05 | 40 |
| GO:003410110 | Cervix | CC | erythrocyte homeostasis | 37/2311 | 129/18723 | 5.16e-07 | 1.93e-05 | 37 |
| GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
| GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
| GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
| GO:003021810 | Cervix | CC | erythrocyte differentiation | 34/2311 | 120/18723 | 2.00e-06 | 6.18e-05 | 34 |
| GO:004887210 | Cervix | CC | homeostasis of number of cells | 61/2311 | 272/18723 | 2.17e-06 | 6.55e-05 | 61 |
| GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
| GO:003166710 | Cervix | CC | response to nutrient levels | 92/2311 | 474/18723 | 5.80e-06 | 1.42e-04 | 92 |
| GO:00092678 | Cervix | CC | cellular response to starvation | 39/2311 | 156/18723 | 1.04e-05 | 2.32e-04 | 39 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SP3 | SNV | Missense_Mutation | c.1030N>A | p.Asp344Asn | p.D344N | Q02447 | protein_coding | tolerated(0.18) | benign(0.011) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SP3 | SNV | Missense_Mutation | c.2128N>T | p.His710Tyr | p.H710Y | Q02447 | protein_coding | tolerated(0.82) | possibly_damaging(0.579) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD | |
| SP3 | SNV | Missense_Mutation | c.518T>G | p.Ile173Arg | p.I173R | Q02447 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| SP3 | SNV | Missense_Mutation | c.2066N>A | p.Arg689His | p.R689H | Q02447 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD | |
| SP3 | SNV | Missense_Mutation | novel | c.1996G>T | p.Asp666Tyr | p.D666Y | Q02447 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E9-A245-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| SP3 | insertion | Frame_Shift_Ins | novel | c.1023_1024insTT | p.Thr342LeufsTer3 | p.T342Lfs*3 | Q02447 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| SP3 | SNV | Missense_Mutation | novel | c.2324C>T | p.Ser775Phe | p.S775F | Q02447 | protein_coding | deleterious(0.01) | probably_damaging(0.915) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| SP3 | SNV | Missense_Mutation | rs761430393 | c.2165N>T | p.Ala722Val | p.A722V | Q02447 | protein_coding | tolerated(0.26) | benign(0) | TCGA-LP-A4AU-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| SP3 | SNV | Missense_Mutation | novel | c.1985T>G | p.Phe662Cys | p.F662C | Q02447 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SP3 | SNV | Missense_Mutation | novel | c.706N>T | p.Val236Phe | p.V236F | Q02447 | protein_coding | deleterious(0) | benign(0.383) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6670 | SP3 | TRANSCRIPTION FACTOR | DOXORUBICIN | DOXORUBICIN | 17511886 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |